Spatial Single‑Cell Platform Reveals Barriers to Antibody Delivery in Solid Tumors
Researchers from Vanderbilt and Stanford have developed a single-cell spatial pharmacology platform to visualize how therapeutic antibodies interact with solid tumors. The study identifies the stromal architecture surrounding tumors as a primary physical barrier to effective drug delivery.
Why it matters
Understanding these physical barriers is crucial for improving the efficacy of cancer treatments and overcoming drug resistance in oncology.
Targeting solid tumors remains one of oncology’s most persistent challenges. Even when a therapeutic antibody is well‑designed, and its molecular target is clear, the drug often struggles to reach its destination inside the dense, heterogeneous architecture of human tumors. Understanding why these agents fail in patients has been a longstanding blind spot in cancer pharmacology.
The article is a technical summary of a scientific study published in a peer-reviewed journal.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in